1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Novo Nordisk A/S - Strategy and SWOT Report

  • November 2015
  • 31 pages
  • MarketLine
Report ID: 3696076

Summary

Table of Contents

Search Inside

Introduction

Novo Nordisk A/S - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Novo Nordisk A/S required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Novo Nordisk A/S in the form of a SWOT analysis

- An in-depth view of the business model of Novo Nordisk A/S including a breakdown and examination of key business segments

- Intelligence on Novo Nordisk A/S’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Novo Nordisk A/S, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Novo Nordisk (or 'the company') is a leading global provider of diabetes products. The company also has a leadership position in hemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk operates in Europe, North America, China, Japan, Korea and other regions of the world. It is headquartered in Bagsvaerd, Denmark, and employed 41,450 people as of December 31, 2014. The company recorded revenues of DKK88,806 million (approximately $15,816.3 million) during the financial year ended December 2014 (FY2014), an increase of 6.3% over FY2013. The operating profit of the company was DKK34,492 million (approximately $6,143 million) in FY2014, an increase of 9.5% over FY2013. The net profit of the company was DKK26,481 million (approximately $4,716.3 million) in FY2014, an increase of 5.2% over FY2013.

Reasons to Purchase:

- Gain understanding of Novo Nordisk A/S and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Novo Nordisk A/S as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Novo Nordisk A/S’s business structure, strategy and prospects

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Women%s Health Cluster Drug Development Pipeline Review, 2017

  • $ 3995
  • Company report
  • May 2017
  • by GBI Research

Women's Health Cluster Drug Development Pipeline Review, 2017 Summary This report provides an overview of the women’s health pipeline landscape. The report provides comprehensive information on the therapeutics ...

Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017

  • $ 3995
  • Company report
  • May 2017
  • by GBI Research

Toxicology Cluster Chemotherapy Related Toxicity Drug Development Pipeline Review, 2017 Summary This report provides an overview of the toxicology pipeline landscape. The report provides comprehensive ...

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017

  • $ 3500
  • Company report
  • May 2017
  • by Global Markets Direct

Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017 Summary Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.